About Bastiaan Kluft

This author has not yet filled in any details.
So far Bastiaan Kluft has created 8 blog entries.

Prof. Dr. Erik Frijlink joins SeraNovo

By |2019-02-06T17:15:42+00:00July, 2018|

Dr Erik Frijlink is a Professor of Pharmaceutical Technology and Biopharmacy at University of Groningen as well as a successful pharmaceutical inventor. With widely recognized expertise in the formulation of poorly soluble small molecules Erik is an excellent addition to the SeraNovo advisory board. Erik’s technical knowledge in formulation science and industry experience will be incredible valuable as we continue to enhance our platform.

SeraNovo acquires MIT Feasibility subsidy

By |2017-06-05T09:23:49+00:00June, 2017|

Using the services of their grant writer, Dr. Coos van Laar from BioTop, SeraNovo have successfully applied and received the MIT Feasibility grant from RVO worth €25.000,-! This money will be well spent on the further development of our platform and for support in the feasibility assessment stage.

 

The MIT Feasibility grant from RVO is a subsidy that combines some R&D and desk research into one grant, aimed at helping SME’s increase their innovative power and support their efforts towards new products. Note that MIT is not to be confused with the Massachusetts Institute of Technology, this is strictly a Dutch government subsidy.

Good Biomarker Sciences Collaboration

By |2017-05-01T09:23:11+00:00May, 2017|

SeraNovo have signed a collaboration agreement with Good Biomarker Sciences B.V. (GBS) detailing the increased collaboration between these two parties. This deal will provide SeraNovo access to GCLP certified laboratory facilities, support on technical validation of their platform and lay the foundation for future collaboration subsidy requests.

 

GBS are a contract research organisation with broad experience and expertise in the fields of immunology, inflammation and haemostasis. GBS have assembled a small but dynamic team capable of supporting SeraNovo in their drug formulation platform development. Generally speaking SeraNovo will develop the platform and GBS will test it efficacy in a broad battery of in vitro analyses.

 

This collaboration will create the initial data sets required for technological validation of SeraNovo’s breakthrough innovation. See our collaboration page for more information about our collaborations.